✦ LIBER ✦

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

✍ Scribed by Gligorov, Joseph; Doval, Dinesh; Bines, José; Alba, Emilio; Cortes, Paulo; Pierga, Jean-Yves; Gupta, Vineet; Costa, Rômulo; Srock, Stefanie; de Ducla, Sabine; Freudensprung, Ulrich; Mustacchi, Giorgio

Book ID: 127378975
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 364 KB
Volume: 15
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(14)70444-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bevacizumab plus paclitaxel versus bevac

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

✍ Lang, Istvan; Brodowicz, Thomas; Ryvo, Larisa; Kahan, Zsuzsanna; Greil, Richard; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 420 KB

Bevacizumab plus chemotherapy versus che

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

✍ von Minckwitz, Gunter; Puglisi, Fabio; Cortes, Javier; Vrdoljak, Eduard; Marschn 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 297 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

## Background: Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (folfiri) is unknow

The Breast Avastin Trial: phase II study

The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer

✍ Bisagni, G.; Musolino, A.; Panebianco, M.; Matteis, A.; Nuzzo, F.; Ardizzoni, A. 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 256 KB